All In Biotech

Drug Trial Radar · NCT07867938

A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)

A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

158

Planned (sponsor's estimate)

Start

Nov 3, 2026

Primary completion

Oct 5, 2029

Study completion Jan 11, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS). This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.

Conditions

  • Pulmonary Sarcoidosis

Interventions

  • TulisokibartDrug

    Subcutaneous (SC) administration

  • PlaceboOther

    SC administration

  • Background prednisone therapyDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Worsening of Pulmonary Sarcoidosis (PS)Time frame: Up to approximately 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Care Access Research Llc ( Site 2725)

    Shreveport, Louisiana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.